| Added by | mollevi |
|---|---|
| Group name | EquipeMY |
| Item Type | Note |
| Note | The following values have no corresponding Zotero field: auth-address: IRCM, Institut de Recherche en Cancerologie de Montpellier, Montpellier, F-34298, France; INSERM, Unit 896, Montpellier, F-34298, France; Universite Montpellier1, Montpellier, F-34298, France; ICM, Montpellier, France. Institut Roche de Recherche et Medecine Translationnelle, Boulogne Bilancourt, France. IRCM, Institut de Recherche en Cancerologie de Montpellier, Montpellier, F-34298, France; INSERM, Unit 896, Montpellier, F-34298, France; Universite Montpellier1, Montpellier, F-34298, France; ICM, Montpellier, France. Unite de Biostatistiques, ICM Val d'Aurelle, Montpellier, France. Department of Biopathology, The Jean Perrin Comprehensive Cancer Center and ERTICa Research Group, University of Auvergne EA4677, Clermont-Ferrand, France. IRCM, Institut de Recherche en Cancerologie de Montpellier, Montpellier, F-34298, France; INSERM, Unit 896, Montpellier, F-34298, France; Universite Montpellier1, Montpellier, F-34298, France; ICM, Montpellier, France. Millegen SA, F-31681, Labege, France. Roche SAS Scientific Partnerships, Boulogne Billancourt, France. CisBio Bioassays, Le Codolet, France. alt-title: Oncotarget number: 16 accession-num: 25216528 |
| Tags | _EndnoteXML import |
| Date Added | 2019/05/22 - 09:42:41 |
| Date Modified | 2019/05/22 - 09:42:41 |
| Parent item | HER3 as biomarker and therapeutic target in pancreatic cancer: new insights in pertuzumab therapy in preclinical models |
Institut de Recherche en Cancérologie de
